



DISCLOSURES AND RESOLUTION OF CONFLICT OF INTEREST

The following faculty members have indicated that they do not have any relevant financial relationships with ineligible companies* to disclose, and have indicated that their presentation or discussion will not include off-label or unapproved product usage.

Guenther Koehne, M.D.

The following individuals involved in the planning, development, review, presentation, authoring and/or editing of the symposium content have disclosed relevant financial relationships with ineligible companies, and the CME department has resolved these potential conflicts of interest. *Indicates that this individual's presentation(s) will include discussion of off-label or unapproved usage.

Juliet Barker, MBBS, faculty for this educational activity, is a researcher with Merck. She is a consultant with New York Blood Center and she is on the speakers' bureau with Gamida. She has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Adam Cohen, M.D., faculty for this educational activity, is a researcher with Novartis, Janssen, GSK and Genentech. He is a consultant for GSK, BMS/Celgene, Genentech/Roche, Janssen, Pfizer, AbbVie, Arcellx and Ichnos. He receives royalties from Novartis. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Corey Cutler, M.D., faculty for this educational activity, is a consultant with Editas, Deciphera, Incyte, Mallinckrodt, Sanofi, Janssen, CTI Biopharma, Jazz, Equillum, Omeros and CSL Behring. He also has individual stocks/stock options with Cimeio and Oxford Immune Algorithmics. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Andrew Evens, D.O., faculty for this educational activity, is a consultant for Novartis, AbbVie and Pharmacyclics. He is an advisor with Seattle Genetics, Hutchmed, Incyte, Daiichi Sankyo and Epizyme. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Nitin Jain, M.D., faculty for this educational activity, is a researcher with Pharmacyclics, AbbVie, Genentech, AstraZeneca, BMS, Pfizer, Servier, ADC Therapeutics, Collectis, Adaptive Biotechnologies, Incyte, Precision Biosciences, Aprea Therapeutics, Fate Therapeutics, Kite/Gilead, Mingsight, Takeda, Medisix, Loxo Oncology, Novalgen, Dialectic Therapeutics, Newave, TransThera Sciences and Novartis. He is a consultant with AbbVie, Adaptive Biotechnologies, AstraZeneca US, BeiGene, Bristol Myers Squibb, CareDx, Collectis, Genentech, Inc., Ipsen US, Janssen Biotech, Kite/Gilead, Pharmacyclics, MEI Pharma, Precision BioSciences, Servier Pharmaceuticals and TG Therapeutics. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Alison Moskowitz, M.D., faculty for this educational activity, is a researcher for ADC Therapeutics, BeiGene, Miragen, Seattle Genetics, Merck, Bristol-Myers Squibb, Incyte, and SecuraBio. She is a consultant with and member of the speakers bureau of Seagen, Affimed, Imbrium Therapeutics L.P./Purdue, Janpix, Merck, Seattle Genetics, and Takeda. She is an advisor for SAB and a member for Lymphoma Hub. She is on the scientific review committee for Gilead Science. She has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Siddhartha Mukherjee, M.D., faculty for this educational activity, is a consultant with Immuneel Therapeutics, Pure Tech, Cellenkos and Brahma Therapeutics. He has stock options with VOR. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Marcelo C. Pasquini, M.D., faculty for this educational activity, is a researcher for BMS, Kite Pharma, Janssen and Novartis. He is a consultant for BMS. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Raajit Rampal, M.D., faculty for this educational activity, is an advisor for Morphosys/Constellation, CTI, Sierra/GSK, Stemline, Blueprint, SDP, Servier, Zentalis, BMS, Galecto, PharmaEssentia and AbbVie. He is on the speakers' bureau for Protagonist and Karyopharm. He is an independent contractor with Morphosys, Stemline, Ryvu and Zentalis. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Yair Reisner, Ph.D., faculty for this educational activity, is a consultant for and receives royalties/patent benefits and individual stocks/stock options with Cell Source Inc. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Paul Richardson, M.D., faculty of this educational activity, is a researcher with Oncopeptides, Celgene/BMS, Karyopharm and Takeda. He is a consultant with Oncopeptides, Celgene/BMS, Karyopharm, Sanofi, Secura Bio, GSK, AstraZeneca, Takeda and Janssen. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Michel Sadelain, M.D., faculty for this educational activity, is a researcher for Takeda Therapeutics, Atarabio, Fate Therapeutics and Mnemo. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Craig Sauter, M.D., faculty for this educational activity, is a researcher for Juno Therapeutics, Celgene/BMS, Bristol-Myers Squibb, Precision Biosciences, Actinium Pharmaceuticals, Sanofi- Genzyme and NKARTA. He is a consultant for Juno Therapeutics, Sanofi-Genzyme, Spectrum Pharmaceuticals, Novartis, Genmab, Precision Biosciences, Kite/a Gilead Company, Celgene/BMS, Gamida Cell, Karyopharm Therapeutics, Ono Pharmaceuticals, MorphoSys, CSL Behring, Syncopation Life Sciences, CRISPR Therapeutics and GSK. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

David Scheinberg, M.D., faculty for this educational activity, is a researcher with Colmmune, Artiva and Eureka. He is an advisor with Eureka, Colmmune, Actinium, Repertoire, Oncopep, Pfizer, Sellas and Sapience. He receives royalties/patent benefits from Sellas, Actinium, Colmmune, Clase and Artiva. He has stock/stock options with Sellas, Actinium, Pfizer, Sapience, Eureka, Colmmune and ISRG. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Gunjan Shah, M.D., faculty for this educational activity, is a researcher with Janssen, Amgen and Beyond Spring. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Robert Soiffer, M.D., faculty for this educational activity is a consultant with Cugene, Jasper, CSL Behring, Neovii, Astellas, Smart Immune, Bluesphere Bio and Vor Biopharma. He is on the board of directors of NMPD – Be the Match. He is also on the board with Juno and BMS. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Eytan Stein, M.D., faculty for this educational activity, is a consultant for Novartis, PinotBio, Janssen, Bristol Myers Squibb, Agios, Jazz, Menarini, Genentech, Genesis, AbbVie, Neoleukin, Gilead, Syndax, OnCusp, CTI Biopharma, Foghorn, Servier, Calithera, Daiichi, Aptose, Syros, Astellas, Ono Pharma, Blueprint. He received an honorarium from Kura; safety monitoring from Epizyme and Cellectis; and research Funding from Eisai and Bristol Myers Squibb. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Wendy Stock, M.D., faculty for this educational activity, is on the advisory board of Agios, Amgen, AstraZeneca, Beam, GSK, Jazz, Kite, Kronos, Kura, Morphosys, Newave, Pfizer, Pluristem, Servier and Syndax. She has received honorariums from Up to Date, Jazz and Pfizer for research to practice. She has received service honorariums from American Society of Hematology. She has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Richard Stone, M.D., faculty for this educational activity, is a consultant for AbbVie, AbbVie/Genentech, Actinium, Aptevo, Arog, AvenCell, BerGen Bio, BMS, Boston Pharmaceuticals, CTI Pharma, Epizyme, GSK, Janssen, Jazz, Kura Onc, Novartis, Syntrix, Syros and Takeda. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Marcel van den Brink, M.D., faculty for this this educational activity, is a researcher with Seres Therapeutics. He is a consultant with Vor Biopharma, Frazier Healthcare Partners, Garuda, Nektar Therapeutics, Notch Therapeutics, Rheos, GSK, Ceramedix, Lyngensis, Pluto Therapeutics and Da Volterra. He is an advisor and has stock options with Thymofox. He receives royalties/patent benefits from Wolters Kluwer. He has an executive role with DKMS. He has stocks/stock options with Seres Therapeutics and Thymofox. IP licensing with Juno and on the advisory board with Smart Immune. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Guenther Koehne, M.D., Summit founder and director of this educational activity, has no relevant financial relationships with ineligible companies* to disclose, and has indicated that the presentation or discussion will not include off-label or unapproved product usage. Other individuals involved in planning, content review, approval, or moderating for this educational activity have no relevant financial relationships to disclose with ineligible companies*.

**Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.*